Evidence map›Paper›PMID 40836945›Full record

ArticleInternational journal of genomics2025

GGTLC1 Is a Prognostic Biomarker in Renal Clear Cell Carcinoma.

Shi Li, Lijun Shi, Xiaofeng Tao, Guanghai Yu, Jianbo Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shi LiDepartment of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID https://orcid.org/0009-0007-9651-3933
Lijun ShiDepartment of Minimally Invasive Surgical Ward of Cholecystitis Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
Xiaofeng TaoDepartment of Pathology, Central Hospital of Dalian University of Technology, Dalian, China.
Guanghai YuDepartment of Urology, Central Hospital of Dalian University of Technology, Dalian, China.
Jianbo WangDepartment of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID https://orcid.org/0000-0002-2667-3946

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney renal clear cell carcinoma (KIRC), the most common type of renal cell carcinoma, is an immunobiologically and metabolically distinct tumor. Its clinical management is closely related to the tumor microenvironment (TME). Identifying its potential markers is important for improving prognosis. Therefore, in this study, we successfully constructed a prognostic model of glutathione metabolism-related molecules and screened for GGTLC1 prognostic molecules, while immunohistochemical analysis of the online database HPA and hospital patient specimens showed that GGTLC1 was highly expressed in paracancerous tissues. Taken together, the results of this study suggest that GGTLC1 is a potential prognostic biomarker associated with KIRC.

Indexed as

GGTLC1kidney renal clear cell carcinomaKIRCprognosis

Identifiers

PMID40836945
PMCPMC12364595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.